Cargando…

JAK‐STAT core cancer pathway: An integrative cancer interactome analysis

Through a comprehensive review and in silico analysis of reported data on STAT‐linked diseases, we analysed the communication pathways and interactome of the seven STATs in major cancer categories and proposed rational targeting approaches for therapeutic intervention to disrupt critical pathways an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erdogan, Fettah, Radu, Tudor Bogdan, Orlova, Anna, Qadree, Abdul Khawazak, de Araujo, Elvin Dominic, Israelian, Johan, Valent, Peter, Mustjoki, Satu M., Herling, Marco, Moriggl, Richard, Gunning, Patrick Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980946/ https://www.ncbi.nlm.nih.gov/pubmed/35229974 http://dx.doi.org/10.1111/jcmm.17228

Ejemplares similares

Direct Targeting Options for STAT3 and STAT5 in Cancer
por: Orlova, Anna, et al.
Publicado: (2019)

Structural and functional consequences of the STAT5B(N642H) driver mutation
por: de Araujo, Elvin D., et al.
Publicado: (2019)

Targeting STAT3 and STAT5 in Cancer
por: de Araujo, Elvin D., et al.
Publicado: (2020)

High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma
por: Garcha, Harsimran Kaur, et al.
Publicado: (2022)

The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma
por: Schönefeldt, Susann, et al.
Publicado: (2021)

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL
por: Wahnschaffe, Linus, et al.
Publicado: (2019)

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
por: Wingelhofer, Bettina, et al.
Publicado: (2018)

Structural Implications of STAT3 and STAT5 SH2 Domain Mutations
por: de Araujo, Elvin D., et al.
Publicado: (2019)

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
por: Toutah, Krimo, et al.
Publicado: (2021)

STAT3 Mutation Is Associated with STAT3 Activation in CD30(+) ALK(−) ALCL
por: Andersson, Emma I., et al.
Publicado: (2020)

Pharmacologic inhibition of STAT5 in acute myeloid leukemia
por: Wingelhofer, Bettina, et al.
Publicado: (2018)

A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation
por: Surbek, Marta, et al.
Publicado: (2021)

STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation
por: Kim, Daehong, et al.
Publicado: (2021)

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
por: Kuusanmäki, Heikki, et al.
Publicado: (2017)

STAT5b in LGL leukemia – a novel therapeutic target?
por: Rajala, Hanna L. M., et al.
Publicado: (2013)

JAK-STAT Signalling Pathway in Cancer
por: Brooks, Andrew J., et al.
Publicado: (2020)

Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
por: Berger, Angelika, et al.
Publicado: (2014)

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas
por: Orlova, Anna, et al.
Publicado: (2017)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

Leptin-Induced JAK/STAT Signaling and Cancer Growth
por: Mullen, McKay, et al.
Publicado: (2016)

Optical chemosensors for the detection of proximally phosphorylated peptides and proteins
por: Cabral, Aaron D., et al.
Publicado: (2021)

Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia
por: Kollmann, Sebastian, et al.
Publicado: (2019)

A JAK/STAT invasion
por: Wells, William A.
Publicado: (2002)

JAK-STAT and bone metabolism
por: Li, Jiliang
Publicado: (2013)

The Drosophila JAK-STAT pathway
por: Zeidler, Martin P, et al.
Publicado: (2013)

Evolution of the JAK-STAT pathway
por: Liongue, Clifford, et al.
Publicado: (2013)

The JAK-STAT pathway at 20
por: Darnell, Jr., James E.
Publicado: (2012)

JAK-STAT in lymphoproliferative disorders
por: Rabadan, Raul, et al.
Publicado: (2015)

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
por: Gleixner, Karoline V., et al.
Publicado: (2017)

JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
por: Mohrherr, Julian, et al.
Publicado: (2019)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD(+) Acute Myeloid Leukemia
por: Bregante, Javier, et al.
Publicado: (2021)

Drosophila Jak/STAT Signaling: Regulation and Relevance in Human Cancer and Metastasis
por: Trivedi, Sunny, et al.
Publicado: (2018)

Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
por: Ni, Yanhong, et al.
Publicado: (2022)

JAK/STAT Signaling and Cervical Cancer: From the Cell Surface to the Nucleus
por: Valle-Mendiola, Arturo, et al.
Publicado: (2023)

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
por: Xue, Chen, et al.
Publicado: (2023)

JAK-STAT in heterochromatin and genome stability
por: Silver-Morse, Louise, et al.
Publicado: (2013)

JAK-STAT and intestinal mucosal immunology
por: Heneghan, Aaron F, et al.
Publicado: (2013)

JAK-STAT: Getting to the heart of the matter
por: Barry, Sean P.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_73ive01fgtitnhphtph46p2893